Non-genomic loss of PTEN function in cancer: not in my genes

Nicholas R Leslie, Michelangelo Foti

Research output: Contribution to journalArticlepeer-review

132 Citations (Scopus)
24 Downloads (Pure)


Loss of function of the phosphatase and tensin homolog (PTEN) tumour suppressor contributes to the development of many cancers. However, in contrast to classical models of tumour suppression, partial loss of PTEN function appears to be frequently observed in the clinic. In addition, studies of both humans and mice with reductions in PTEN gene dosage indicate that even partial loss of PTEN function is sufficient to promote some cancer types, particularly in the breast. PTEN expression appears to be tightly controlled both transcriptionally and post-transcriptionally, with several recent studies implicating oncogenic microRNAs in PTEN suppression. The lipid phosphatase activity of PTEN can also be regulated post-translationally via inhibitory phosphorylation, ubiquitination or oxidation. Here we discuss these multiple mechanisms of PTEN regulation. We also put into context recent proposals that changes in this regulation can drive tumour development and address the accompanying evidence for their clinical significance.
Original languageEnglish
Pages (from-to)131-140
Number of pages10
JournalTrends in Pharmacological Sciences
Issue number3
Publication statusPublished - Mar 2011


Dive into the research topics of 'Non-genomic loss of PTEN function in cancer: not in my genes'. Together they form a unique fingerprint.

Cite this